Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma

NCT04989803 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT04989803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04989803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
Lead sponsor
Kite, A Gilead Company
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 27, 2021
Completion date
February 28, 2030
Enrollment
247 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or refractory b-cell lymphoma